Key Points
- Charles River Laboratories EVP Shannon Parisotto sold 3,714 shares at an average price of $279.66, generating approximately $1.04 million. The transaction, conducted under a pre-arranged Rule 10b5-1 plan, reduced the executive’s holdings by 43.59% to 4,807 shares.
- CRL recently reported quarterly EPS of $3.02, exceeding analyst estimates of $2.77, while revenue reached $1 billion but declined 2.7% year over year. The company issued fiscal 2026 EPS guidance of $11.15 to $11.45.
- The stock opened at $281.78, near its 12-month high of $288.02, and analysts maintain a consensus “Moderate Buy” rating with an average price target of $255.65.
Charles River Laboratories International, Inc. (NYSE:CRL - Get Free Report) EVP Shannon Parisotto sold 3,714 shares of the business's stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $279.66, for a total transaction of $1,038,657.24. Following the completion of the sale, the executive vice president owned 4,807 shares in the company, valued at approximately $1,344,325.62. This trade represents a 43.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Charles River Laboratories International Trading Down 0.9%
NYSE CRL opened at $281.78 on Friday. The company has a debt-to-equity ratio of 0.92, a current ratio of 1.35 and a quick ratio of 1.04. The stock has a market capitalization of $13.45 billion, a P/E ratio of -58.10, a PEG ratio of 2.95 and a beta of 1.38. The firm's 50-day moving average is $222.90 and its two-hundred day moving average is $190.70. Charles River Laboratories International, Inc. has a 12 month low of $144.26 and a 12 month high of $288.02.
Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, August 5th. The medical research company reported $3.02 earnings per share for the quarter, beating analysts' consensus estimates of $2.77 by $0.25. The business had revenue of $1 billion during the quarter, compared to analysts' expectations of $980.53 million. Charles River Laboratories International had a negative net margin of 5.96% and a positive return on equity of 15.75%. The business's revenue for the quarter was down 2.7% on a year-over-year basis. During the same period last year, the business earned $3.12 earnings per share. Charles River Laboratories International has set its FY 2026 guidance at 11.150-11.450 EPS. On average, sell-side analysts anticipate that Charles River Laboratories International, Inc. will post 11.35 earnings per share for the current year.
Hedge Funds Weigh In On Charles River Laboratories International
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Madison Asset Management LLC acquired a new position in shares of Charles River Laboratories International in the second quarter worth $3,805,000. Great Lakes Advisors LLC purchased a new position in Charles River Laboratories International in the second quarter worth approximately $459,000. Trust Asset Management LLC acquired a new position in Charles River Laboratories International during the 2nd quarter worth approximately $129,000. Handelsbanken Fonder AB raised its holdings in shares of Charles River Laboratories International by 36.9% in the 2nd quarter. Handelsbanken Fonder AB now owns 19,306 shares of the medical research company's stock valued at $4,378,000 after purchasing an additional 5,200 shares in the last quarter. Finally, Czech National Bank grew its stake in shares of Charles River Laboratories International by 2.3% during the second quarter. Czech National Bank now owns 13,710 shares of the medical research company's stock worth $3,109,000 after purchasing an additional 307 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company's stock.
Analyst Ratings Changes
A number of analysts have issued reports on the company. Mizuho set a $264.00 target price on Charles River Laboratories International in a research report on Monday. Morgan Stanley raised their price target on Charles River Laboratories International from $260.00 to $300.00 and gave the stock an "overweight" rating in a research report on Friday, August 7th. Piper Sandler set a $300.00 price objective on Charles River Laboratories International in a research note on Monday. Royal Bank Of Canada boosted their price objective on Charles River Laboratories International from $215.00 to $282.00 and gave the company an "outperform" rating in a report on Thursday, August 6th. Finally, Citigroup reissued a "buy" rating on shares of Charles River Laboratories International in a research note on Wednesday, July 8th. Twelve equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $255.65.
View Our Latest Stock Analysis on Charles River Laboratories International
About Charles River Laboratories International
(
Get Free Report)
Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company's core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.
Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
